Drug Profile


Alternative Names: PXT 864

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioSystems International; INSERM; Pharnext; University of Bordeaux
  • Developer Pharnext
  • Class Alkanesulfonic-acids; Aminobutyric acids; Antiparkinsonians; Antispastics; Muscle relaxants; Nootropics; Small molecules
  • Mechanism of Action GABA B receptor agonists; GABA receptor agonists; Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease
  • Phase I Amyotrophic lateral sclerosis; Parkinson's disease
  • Discontinued Memory disorders

Most Recent Events

  • 26 Sep 2017 PXT 864 is still in phase II trials for Alzheimer's disease in France (Pharnext website, September 2017)
  • 16 Jul 2017 Efficacy and adverse events data from the phase II PLEODIAL trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
  • 26 May 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top